Literature DB >> 9051162

Dexamethasone augmentation in treatment-resistant depression.

T G Dinan1, E Lavelle, J Cooney, F Burnett, L Scott, A Dash, J Thakore, C Berti.   

Abstract

A total of 10 patients who fulfilled DSM-III-R criteria for major depression were recruited to the study, each of whom had failed to respond to a 6-week course of treatment with either sertraline or fluoxetine. Each subject had baseline serum cortisol measurements together with a Hamilton depression (HAMD) score. All patients were started on dexamethasone (3 mg daily) for 4 days, while remaining on their antidepressant treatment. Further Hamilton ratings were made on days 5 and 21. Six patients showed a significant improvement, whilst two showed a minimal response. A good clinical response was associated with a high baseline cortisol level.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9051162     DOI: 10.1111/j.1600-0447.1997.tb00374.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  18 in total

1.  Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients.

Authors:  Cornelius Schüle; Thomas C Baghai; Daniela Eser; Peter Zwanzger; Martina Jordan; Renate Buechs; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2006-04-22       Impact factor: 4.530

2.  The effects of a combination of intravenous dexamethasone and ketamine on postoperative mood in patients undergoing laparoscopically assisted-gynecologic surgery.

Authors:  Cheol Lee; Juhwan Lee; Gilho Lee; Hayeong Lee; Zhou Shicheng; Jihyo Hwang
Journal:  Psychopharmacology (Berl)       Date:  2018-06-14       Impact factor: 4.530

Review 3.  The glucocorticoid receptor: pivot of depression and of antidepressant treatment?

Authors:  Christoph Anacker; Patricia A Zunszain; Livia A Carvalho; Carmine M Pariante
Journal:  Psychoneuroendocrinology       Date:  2011-04       Impact factor: 4.905

4.  Behavioral effects of glucocorticoids during the first exposures to the forced swim stress.

Authors:  Galina T Shishkina; Veta V Bulygina; Nikolay N Dygalo
Journal:  Psychopharmacology (Berl)       Date:  2014-08-20       Impact factor: 4.530

Review 5.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 6.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 7.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 8.  A final common pathway for depression? Progress toward a general conceptual framework.

Authors:  Eric A Stone; Yan Lin; David Quartermain
Journal:  Neurosci Biobehav Rev       Date:  2007-10-10       Impact factor: 8.989

9.  Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters.

Authors:  Carmine M Pariante; Richard B Kim; Andrew Makoff; Robert W Kerwin
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers.

Authors:  Carmine M Pariante; Andrew S Papadopoulos; Lucia Poon; Anthony J Cleare; Stuart A Checkley; Judie English; Robert W Kerwin; Stafford Lightman
Journal:  Psychopharmacology (Berl)       Date:  2004-06-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.